High frequency deep brain stimulation of the subthalamic nucleus versus continuous subcutaneous apomorphine infusion therapy: a review
- PMID: 21190050
- DOI: 10.1007/s00702-010-0556-7
High frequency deep brain stimulation of the subthalamic nucleus versus continuous subcutaneous apomorphine infusion therapy: a review
Abstract
In advanced Parkinson's disease, several therapeutical option including not only lesional surgery (VIM, GPi) and deep brain stimulation (STN, GPi, VIM) but also continuous subcutaneous apomorphine infusion therapy can be proposed to the patient. The choice depends on the hope of the patient, patient's general health condition and the experience and choice of the neurosurgical and neurologist team. Here we report our experience based on 400 STN-DBS cases and we discuss, on the basis of our experience and on the literature, the advantage and disadvantage of DBS strategy as compared with non-surgical option such as continuous subcutaneous apomorphine infusion therapy.
Similar articles
-
Treatment of motor fluctuations in Parkinson's disease.J Neural Transm (Vienna). 2011 Jun;118(6):905-6. doi: 10.1007/s00702-011-0661-2. J Neural Transm (Vienna). 2011. PMID: 21617891 Free PMC article. No abstract available.
-
What is the best treatment for fluctuating Parkinson's disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus?J Neural Transm (Vienna). 2011 Jun;118(6):907-14. doi: 10.1007/s00702-010-0555-8. Epub 2010 Dec 25. J Neural Transm (Vienna). 2011. PMID: 21188435 Review.
-
Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease.Arch Neurol. 2005 Apr;62(4):554-60. doi: 10.1001/archneur.62.4.554. Arch Neurol. 2005. PMID: 15824252 Clinical Trial.
-
Deep brain stimulation and continuous dopaminergic stimulation in advanced Parkinson's disease.Parkinsonism Relat Disord. 2007 Sep;13 Suppl:S18-23. doi: 10.1016/j.parkreldis.2007.06.006. Epub 2007 Aug 16. Parkinsonism Relat Disord. 2007. PMID: 17702631 Review.
-
Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up.Brain. 2005 Oct;128(Pt 10):2240-9. doi: 10.1093/brain/awh571. Epub 2005 Jun 23. Brain. 2005. PMID: 15975946 Clinical Trial.
Cited by
-
The pharmacological properties and therapeutic use of apomorphine.Molecules. 2012 May 7;17(5):5289-309. doi: 10.3390/molecules17055289. Molecules. 2012. PMID: 22565480 Free PMC article. Review.
-
Continuous subcutaneous apomorphine in advanced Parkinson's disease patients treated with deep brain stimulation.J Neurol. 2019 Mar;266(3):659-666. doi: 10.1007/s00415-019-09184-5. Epub 2019 Jan 7. J Neurol. 2019. PMID: 30617907
-
Access to device-aided therapies in advanced Parkinson's disease: navigating clinician biases, patient preference, and prognostic uncertainty.J Neural Transm (Vienna). 2023 Nov;130(11):1411-1432. doi: 10.1007/s00702-023-02668-9. Epub 2023 Jul 12. J Neural Transm (Vienna). 2023. PMID: 37436446 Free PMC article. Review.
-
Subthalamic nucleus and globus pallidus internus stimulation for the treatment of Parkinson's disease: A systematic review.J Int Med Res. 2017 Oct;45(5):1602-1612. doi: 10.1177/0300060517708102. Epub 2017 Jul 12. J Int Med Res. 2017. PMID: 28701061 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous